Skip to main content

Data Explorer

Research historical outbreak investigations and the full recall archive, with charts, trends, and advanced filters. Looking for what's happening right now instead? See current Health Alerts.

Recall totals

All FDA and USDA recalls in Public Health Trace, June 2012 to September 2026.

37,204
Total recall recordsAll FDA and USDA recalls in Public Health Trace
9,841
Class I recallsReasonable probability of serious health consequences
24,366
Class II recallsTemporary or medically reversible health consequences
2,892
Class III recallsNot likely to cause adverse health consequences

Quick insights

A snapshot of the most notable patterns across all recorded FDA and USDA recalls.

Most recalled product100 vegetarian Fenugreek Capsules 90 count, 600mg, packaged in 150cc Amber Glass Packer with White Polypropylene Cap. 53 recalls
Most common hazardLack of Assurance of Sterility 2,073 recalls
Most affected stateHawaii 200 recalls mention this state

Download matching recalls as CSV

CSV exports include up to 5,000 matching rows (applying your current filters), not the full dataset if it's larger.

Filters
Recall details
Location
Date range
Sort results
Clear filters
Metric
View
Recalls announced by month (Year to date)

A chart of recalls grouped by month.

Download CSV

Source: FDA and USDA public dataLast updated

Summary (Year to date)

  • 1,714 recalls have been announced year to date.
  • Sep 2026 was 3% higher than the previous complete period (Aug 2026: 182).
  • The highest complete period was Jun 2026 (297).
  • Oct 2026 is incomplete and not included in the figures above.
  • Complete data
  • Incomplete
Recalls by class

A bar chart of the total number of recalls in this dataset by recall class.

Recalls by class
ClassRecalls
Class II24,366
Class I9,841
Class III2,892
Not Yet Classified2
Download CSV
Recalls by class
ClassRecalls
Class II24,366
Class I9,841
Class III2,892
Not Yet Classified2

Showing 16,461–16,480 of 17,350 recalls

FDA Recall Ongoing Historical recordClass II

MICC (Methionine, Inositol, Choline, Cyanocobalamin, Chromium) Inj and MICC 25/50/330 Inj, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Methylcobalamin 1 mg/ml / Folic Acid 2.5 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Meloxicam 5 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Lisinopril 20 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Ketoprofen Solution 10% Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Estradiol Cypionate 2 mg/ml Test Cyp 50 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Ceftiofur GM vial 50 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Buprenorphine 0.3 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Atipamezole 10 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Amikacin Sulfate 250 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall Terminated Historical recordClass III

Nicardipine Hydrochloride Injection 25 mg/10 mL (2.5 mg/mL), 10 mL single-use vials, Rx Only, Mfd. by Exela Pharma Sciences, LLC, Lenoir, NC, Dist. by: West-ward Pharmaceutical Corp., Eatontown, NJ --- NDC 0143-9689-10

by West-Ward Pharmaceutical Corp.

Reason
Failed Impurity/Degradation Specifications; out of specification value for impurity Nitrophenylpuridine Derivative (NPP-D)
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Nimodipine Capsules 30 mg, Rx Only, For Institutional Use Only, a) 30-count unit dose Capsules (5x6 blister cards per carton), NDC 57664-135-64, b) 100-count unit dose Capsules (25x4 blister cards per carton), NDC 57664-135-65, Distributed by: Caraco Pharmaceutical Laboratories, Ltd. Detroit, MI 48202 Affiliate of Sun Pharmaceutical Industries, Inc.

by Sun Pharmaceutical Industries Inc.

Reason
Crystallization; crystallized nimodipine
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall Terminated Historical recordClass III

Balziva(TM) (norethindrone and ethinyl estradiol tablets, USP) 0.15 mg/0.03 mg, 28 day regimen, Rx only, Barr Laboratories, Inc., Pomona, NY --- NDC 0555-9034-58

by Teva Pharmaceuticals USA, Inc.

Reason
Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall Terminated Historical recordClass III

Jolessa(R) (levonorgestrel/ethinyl estradiol tablets, USP) 0.15 mg/0.03 mg, 91 day regimen, Rx only, Manufactured by Barr Laboratories, Inc., Pomona, NY, manufactured for TEVA Pharmaceuticals USA, Sellersville, PA ---NDC 0555-9123-66

by Teva Pharmaceuticals USA, Inc.

Reason
Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Yohimbine 10 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Xylazine 300 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Vitamin B12 Cyanocobalamin 5000 mcg Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Vitamin B12 (3000 mcg/ml & 5000 mcg/ml) Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Vitamin A/D3/E Olive Oil Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Vitamin 15 (HEMO15) Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

Data last updated:

Recall records are summarized from official FDA and USDA sources. Notices may be updated, reclassified, terminated, or withdrawn. Always review the linked official notice for the most current instructions. Read the full medical disclaimer.